Charles Schwab
LAB icon

Charles Schwab’s Standard BioTools LAB Stock Holding History

Charles Schwab’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Sell
1,759,038
-655,661
-27% -$620K ﹤0.01% 2895
2026
Q1 		$2.22M Sell
2,414,699
-93,365
-4% -$113K ﹤0.01% 2690
2025
Q4 		$3.21M Buy
2,508,064
+3,884
+0.2% +$5.22K ﹤0.01% 2615
2025
Q3 		$3.26M Sell
2,504,180
-37,718
-1% -$49.4K ﹤0.01% 2606
2025
Q2 		$3.05M Buy
2,541,898
+98,838
+4% +$110K ﹤0.01% 2534
2025
Q1 		$2.64M Buy
2,443,060
+110,411
+5% +$155K ﹤0.01% 2525
2024
Q4 		$4.08M Sell
2,332,649
-112,434
-5% -$209K ﹤0.01% 2427
2024
Q3 		$4.72M Buy
2,445,083
+1,597,728
+189% +$3.13M ﹤0.01% 2401
2024
Q2 		$1.5M Buy
847,355
+735,771
+659% +$1.8M ﹤0.01% 2788
2024
Q1 		$302K Buy
111,584
+80,392
+258% +$194K ﹤0.01% 3175
2023
Q4 		$68.9K Hold
31,192
– – ﹤0.01% 3372
2023
Q3 		$90.5K Hold
31,192
– – ﹤0.01% 3365
2023
Q2 		$60.2K Hold
31,192
– – ﹤0.01% 3395
2023
Q1 		$60.8K Buy
+31,192
New +$61.6K ﹤0.01% 3317
2022
Q4 		– Sell
-27,127
Closed -$30K – 3556
2022
Q3 		$30K Hold
27,127
– – ﹤0.01% 3435
2022
Q2 		$44K Sell
27,127
-170,026
-86% -$421K ﹤0.01% 3408
2022
Q1 		$708K Buy
197,153
+5,688
+3% +$19.6K ﹤0.01% 2986
2021
Q4 		$751K Hold
191,465
– – ﹤0.01% 3019
2021
Q3 		$1.26M Buy
191,465
+5,362
+3% +$35.3K ﹤0.01% 2795
2021
Q2 		$1.15M Buy
186,103
+455
+0.2% +$2.43K ﹤0.01% 2880
2021
Q1 		$840K Buy
185,648
+4,266
+2% +$23.4K ﹤0.01% 2909
2020
Q4 		$1.09M Buy
181,382
+14,652
+9% +$96.3K ﹤0.01% 2746
2020
Q3 		$1.24M Sell
166,730
-5,693
-3% -$39.3K ﹤0.01% 2625
2020
Q2 		$692K Buy
172,423
+6,091
+4% +$21.2K ﹤0.01% 2732
2020
Q1 		$423K Sell
166,332
-411
-0.2% -$1.35K ﹤0.01% 2772
2019
Q4 		$581K Hold
166,743
– – ﹤0.01% 2771
2019
Q3 		$773K Buy
166,743
+2,454
+1% +$19.3K ﹤0.01% 2640
2019
Q2 		$2.02M Buy
164,289
+78,104
+91% +$995K ﹤0.01% 2368
2019
Q1 		$1.15M Buy
86,185
+12,966
+18% +$137K ﹤0.01% 2519
2018
Q4 		$632K Buy
73,219
+13,419
+22% +$105K ﹤0.01% 2683
2018
Q3 		$448K Buy
59,800
+5,100
+9% +$36.3K ﹤0.01% 2878
2018
Q2 		$327K Sell
54,700
-17,100
-24% -$97.5K ﹤0.01% 2930
2018
Q1 		$420K Hold
71,800
– – ﹤0.01% 2776
2017
Q4 		$423K Buy
71,800
+15,800
+28% +$86.5K ﹤0.01% 2770
2017
Q3 		$283K Sell
56,000
-8,155
-13% -$34.3K ﹤0.01% 2897
2017
Q2 		$260K Sell
64,155
-11,580
-15% -$54.9K ﹤0.01% 2922
2017
Q1 		$431K Sell
75,735
-24,150
-24% -$153K ﹤0.01% 2695
2016
Q4 		$728K Buy
99,885
+5,236
+6% +$32.9K ﹤0.01% 2532
2016
Q3 		$759K Buy
94,649
+4,372
+5% +$40.2K ﹤0.01% 2475
2016
Q2 		$816K Buy
90,277
+1,344
+2% +$12.6K ﹤0.01% 2411
2016
Q1 		$718K Buy
88,933
+1,632
+2% +$11.8K ﹤0.01% 2456
2015
Q4 		$944K Buy
87,301
+2,080
+2% +$20.4K ﹤0.01% 2415
2015
Q3 		$692K Sell
85,221
-1,215
-1% -$19.1K ﹤0.01% 2504
2015
Q2 		$2.09M Buy
86,436
+5,831
+7% +$184K ﹤0.01% 2070
2015
Q1 		$3.39M Buy
80,605
+3,757
+5% +$149K ﹤0.01% 1758
2014
Q4 		$2.59M Buy
76,848
+2,681
+4% +$75.9K ﹤0.01% 1860
2014
Q3 		$1.82M Buy
74,167
+1,636
+2% +$46K ﹤0.01% 2013
2014
Q2 		$2.13M Sell
72,531
-214
-0.3% -$6.86K ﹤0.01% 1956
2014
Q1 		$3.21M Buy
72,745
+1,917
+3% +$84.3K 0.01% 1664
2013
Q4 		$2.71M Buy
70,828
+6,594
+10% +$194K 0.01% 1714
2013
Q3 		$1.42M Buy
64,234
+4,425
+7% +$86.9K ﹤0.01% 2034
2013
Q2 		$1.02M Buy
+59,809
New +$1.05M ﹤0.01% 2153

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Charles Schwab's LAB Position: Q2 2026 in Review

Charles Schwab reduced its Standard BioTools (LAB) stake by 27% in Q2 2026, selling an estimated $620K and leaving 1,759,038 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Charles Schwab first reported a position in LAB in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.72M in Q3 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Charles Schwab held 1,759,038 shares of Standard BioTools worth $1.45M as of Q2 2026.
  • Charles Schwab sold 655,661 Standard BioTools shares in Q2 2026, an estimated $620K.
  • Standard BioTools made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2895 holding.
  • Charles Schwab first reported a position in Standard BioTools in Q2 2013 and has held it in 52 quarters since.
  • Charles Schwab's Standard BioTools position peaked at $4.72M in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.